Skip to main content
Top
Published in: Virology Journal 1/2010

Open Access 01-12-2010 | Research

An H5N1 M2e-based multiple antigenic peptide vaccine confers heterosubtypic protection from lethal infection with pandemic 2009 H1N1 virus

Authors: Guangyu Zhao, Shihui Sun, Lanying Du, Wenjun Xiao, Zhitao Ru, Zhihua Kou, Yan Guo, Hong Yu, Shibo Jiang, Yuchun Lone, Bo-Jian Zheng, Yusen Zhou

Published in: Virology Journal | Issue 1/2010

Login to get access

Abstract

Background

A 2009 global influenza pandemic caused by a novel swine-origin H1N1 influenza A virus has posted an increasing threat of a potential pandemic by the highly pathogenic avian influenza (HPAI) H5N1 virus, driving us to develop an influenza vaccine which confers cross-protection against both H5N1 and H1N1 viruses. Previously, we have shown that a tetra-branched multiple antigenic peptide (MAP) vaccine based on the extracellular domain of M2 protein (M2e) from H5N1 virus (H5N1-M2e-MAP) induced strong immune responses and cross-protection against different clades of HPAI H5N1 viruses. In this report, we investigated whether such M2e-MAP presenting the H5N1-M2e consensus sequence can afford heterosubtypic protection from lethal challenge with the pandemic 2009 H1N1 virus.

Results

Our results demonstrated that H5N1-M2e-MAP plus Freund's or aluminum adjuvant induced strong cross-reactive IgG antibody responses against M2e of the pandemic H1N1 virus which contains one amino acid variation with M2e of H5N1 at position 13. These cross-reactive antibodies may maintain for 6 months and bounced back quickly to the previous high level after the 2nd boost administered 2 weeks before virus challenge. H5N1-M2e-MAP could afford heterosubtypic protection against lethal challenge with pandemic H1N1 virus, showing significant decrease of viral replications and obvious alleviation of histopathological damages in the challenged mouse lungs. 100% and 80% of the H5N1-M2e-MAP-vaccinated mice with Freund's and aluminum adjuvant, respectively, survived the lethal challenge with pandemic H1N1 virus.

Conclusions

Our results suggest that H5N1-M2e-MAP has a great potential to prevent the threat from re-emergence of pandemic H1N1 influenza and possible novel influenza pandemic due to the reassortment of HPAI H5N1 virus with the 2009 swine-origin H1N1 influenza virus.
Appendix
Available only for authorised users
Literature
4.
go back to reference WHO: Antigenic and genetic characteristics of influenza A(H5N1) and influenza A(H9N2) viruses and candidate vaccine viruses developed for potential use in human vaccines - February 2010. Wkly Epidemiol Rec 85: 100-107. WHO: Antigenic and genetic characteristics of influenza A(H5N1) and influenza A(H9N2) viruses and candidate vaccine viruses developed for potential use in human vaccines - February 2010. Wkly Epidemiol Rec 85: 100-107.
5.
go back to reference Garten RJ, Davis CT, Russell CA, Shu B, Lindstrom S, Balish A, Sessions WM, Xu X, Skepner E, Deyde V, et al.: Antigenic and genetic characteristics of swine-origin 2009 A(H1N1) influenza viruses circulating in humans. Science 2009, 325: 197-201. 10.1126/science.1176225PubMedPubMedCentralCrossRef Garten RJ, Davis CT, Russell CA, Shu B, Lindstrom S, Balish A, Sessions WM, Xu X, Skepner E, Deyde V, et al.: Antigenic and genetic characteristics of swine-origin 2009 A(H1N1) influenza viruses circulating in humans. Science 2009, 325: 197-201. 10.1126/science.1176225PubMedPubMedCentralCrossRef
6.
go back to reference Du L, Zhou Y, Jiang S: Research and development of universal influenza vaccines. Microbes Infect 12: 280-286. 10.1016/j.micinf.2010.01.001 Du L, Zhou Y, Jiang S: Research and development of universal influenza vaccines. Microbes Infect 12: 280-286. 10.1016/j.micinf.2010.01.001
7.
go back to reference Neirynck S, Deroo T, Saelens X, Vanlandschoot P, Jou WM, Fiers W: A universal influenza A vaccine based on the extracellular domain of the M2 protein. Nat Med 1999, 5: 1157-1163. 10.1038/13484PubMedCrossRef Neirynck S, Deroo T, Saelens X, Vanlandschoot P, Jou WM, Fiers W: A universal influenza A vaccine based on the extracellular domain of the M2 protein. Nat Med 1999, 5: 1157-1163. 10.1038/13484PubMedCrossRef
8.
go back to reference Bessa J, Schmitz N, Hinton HJ, Schwarz K, Jegerlehner A, Bachmann MF: Efficient induction of mucosal and systemic immune responses by virus-like particles administered intranasally: implications for vaccine design. Eur J Immunol 2008, 38: 114-126. 10.1002/eji.200636959PubMedCrossRef Bessa J, Schmitz N, Hinton HJ, Schwarz K, Jegerlehner A, Bachmann MF: Efficient induction of mucosal and systemic immune responses by virus-like particles administered intranasally: implications for vaccine design. Eur J Immunol 2008, 38: 114-126. 10.1002/eji.200636959PubMedCrossRef
9.
go back to reference Denis J, Acosta-Ramirez E, Zhao Y, Hamelin ME, Koukavica I, Baz M, Abed Y, Savard C, Pare C, Lopez Macias C, et al.: Development of a universal influenza A vaccine based on the M2e peptide fused to the papaya mosaic virus (PapMV) vaccine platform. Vaccine 2008, 26: 3395-3403. 10.1016/j.vaccine.2008.04.052PubMedCrossRef Denis J, Acosta-Ramirez E, Zhao Y, Hamelin ME, Koukavica I, Baz M, Abed Y, Savard C, Pare C, Lopez Macias C, et al.: Development of a universal influenza A vaccine based on the M2e peptide fused to the papaya mosaic virus (PapMV) vaccine platform. Vaccine 2008, 26: 3395-3403. 10.1016/j.vaccine.2008.04.052PubMedCrossRef
10.
go back to reference Eliasson DG, El Bakkouri K, Schon K, Ramne A, Festjens E, Lowenadler B, Fiers W, Saelens X, Lycke N: CTA1-M2e-DD: a novel mucosal adjuvant targeted influenza vaccine. Vaccine 2008, 26: 1243-1252. 10.1016/j.vaccine.2007.12.027PubMedCrossRef Eliasson DG, El Bakkouri K, Schon K, Ramne A, Festjens E, Lowenadler B, Fiers W, Saelens X, Lycke N: CTA1-M2e-DD: a novel mucosal adjuvant targeted influenza vaccine. Vaccine 2008, 26: 1243-1252. 10.1016/j.vaccine.2007.12.027PubMedCrossRef
11.
go back to reference De Filette M, Martens W, Roose K, Deroo T, Vervalle F, Bentahir M, Vandekerckhove J, Fiers W, Saelens X: An influenza A vaccine based on tetrameric ectodomain of matrix protein 2. J Biol Chem 2008, 283: 11382-11387. 10.1074/jbc.M800650200PubMedPubMedCentralCrossRef De Filette M, Martens W, Roose K, Deroo T, Vervalle F, Bentahir M, Vandekerckhove J, Fiers W, Saelens X: An influenza A vaccine based on tetrameric ectodomain of matrix protein 2. J Biol Chem 2008, 283: 11382-11387. 10.1074/jbc.M800650200PubMedPubMedCentralCrossRef
12.
go back to reference Huleatt JW, Nakaar V, Desai P, Huang Y, Hewitt D, Jacobs A, Tang J, McDonald W, Song L, Evans RK, et al.: Potent immunogenicity and efficacy of a universal influenza vaccine candidate comprising a recombinant fusion protein linking influenza M2e to the TLR5 ligand flagellin. Vaccine 2008, 26: 201-214. 10.1016/j.vaccine.2007.10.062PubMedCrossRef Huleatt JW, Nakaar V, Desai P, Huang Y, Hewitt D, Jacobs A, Tang J, McDonald W, Song L, Evans RK, et al.: Potent immunogenicity and efficacy of a universal influenza vaccine candidate comprising a recombinant fusion protein linking influenza M2e to the TLR5 ligand flagellin. Vaccine 2008, 26: 201-214. 10.1016/j.vaccine.2007.10.062PubMedCrossRef
13.
go back to reference Laddy DJ, Yan J, Kutzler M, Kobasa D, Kobinger GP, Khan AS, Greenhouse J, Sardesai NY, Draghia-Akli R, Weiner DB: Heterosubtypic protection against pathogenic human and avian influenza viruses via in vivo electroporation of synthetic consensus DNA antigens. PLoS One 2008, 3: e2517. 10.1371/journal.pone.0002517PubMedPubMedCentralCrossRef Laddy DJ, Yan J, Kutzler M, Kobasa D, Kobinger GP, Khan AS, Greenhouse J, Sardesai NY, Draghia-Akli R, Weiner DB: Heterosubtypic protection against pathogenic human and avian influenza viruses via in vivo electroporation of synthetic consensus DNA antigens. PLoS One 2008, 3: e2517. 10.1371/journal.pone.0002517PubMedPubMedCentralCrossRef
14.
go back to reference Fan J, Liang X, Horton MS, Perry HC, Citron MP, Heidecker GJ, Fu TM, Joyce J, Przysiecki CT, Keller PM, et al.: Preclinical study of influenza virus A M2 peptide conjugate vaccines in mice, ferrets, and rhesus monkeys. Vaccine 2004, 22: 2993-3003. 10.1016/j.vaccine.2004.02.021PubMedCrossRef Fan J, Liang X, Horton MS, Perry HC, Citron MP, Heidecker GJ, Fu TM, Joyce J, Przysiecki CT, Keller PM, et al.: Preclinical study of influenza virus A M2 peptide conjugate vaccines in mice, ferrets, and rhesus monkeys. Vaccine 2004, 22: 2993-3003. 10.1016/j.vaccine.2004.02.021PubMedCrossRef
15.
go back to reference Mozdzanowska K, Feng J, Eid M, Kragol G, Cudic M, Otvos L Jr, Gerhard W: Induction of influenza type A virus-specific resistance by immunization of mice with a synthetic multiple antigenic peptide vaccine that contains ectodomains of matrix protein 2. Vaccine 2003, 21: 2616-2626. 10.1016/S0264-410X(03)00040-9PubMedCrossRef Mozdzanowska K, Feng J, Eid M, Kragol G, Cudic M, Otvos L Jr, Gerhard W: Induction of influenza type A virus-specific resistance by immunization of mice with a synthetic multiple antigenic peptide vaccine that contains ectodomains of matrix protein 2. Vaccine 2003, 21: 2616-2626. 10.1016/S0264-410X(03)00040-9PubMedCrossRef
16.
go back to reference Tam JP: Synthetic peptide vaccine design: synthesis and properties of a high-density multiple antigenic peptide system. Proc Natl Acad Sci USA 1988, 85: 5409-5413. 10.1073/pnas.85.15.5409PubMedPubMedCentralCrossRef Tam JP: Synthetic peptide vaccine design: synthesis and properties of a high-density multiple antigenic peptide system. Proc Natl Acad Sci USA 1988, 85: 5409-5413. 10.1073/pnas.85.15.5409PubMedPubMedCentralCrossRef
17.
go back to reference Wang CY, Looney DJ, Li ML, Walfield AM, Ye J, Hosein B, Tam JP, Wong-Staal F: Long-term high-titer neutralizing activity induced by octameric synthetic HIV-1 antigen. Science 1991, 254: 285-288. 10.1126/science.1925584PubMedCrossRef Wang CY, Looney DJ, Li ML, Walfield AM, Ye J, Hosein B, Tam JP, Wong-Staal F: Long-term high-titer neutralizing activity induced by octameric synthetic HIV-1 antigen. Science 1991, 254: 285-288. 10.1126/science.1925584PubMedCrossRef
18.
go back to reference Zhao G, Lin Y, Du L, Guan J, Sun S, Sui H, Kou Z, Chan CC, Guo Y, Jiang S, et al.: An M2e-based multiple antigenic peptide vaccine protects mice from lethal challenge with divergent H5N1 influenza viruses. Virol J 7: 9. 10.1186/1743-422X-7-9 Zhao G, Lin Y, Du L, Guan J, Sun S, Sui H, Kou Z, Chan CC, Guo Y, Jiang S, et al.: An M2e-based multiple antigenic peptide vaccine protects mice from lethal challenge with divergent H5N1 influenza viruses. Virol J 7: 9. 10.1186/1743-422X-7-9
19.
go back to reference Schotsaert M, De Filette M, Fiers W, Saelens X: Universal M2 ectodomain-based influenza A vaccines: preclinical and clinical developments. Expert Rev Vaccines 2009, 8: 499-508. 10.1586/erv.09.6PubMedPubMedCentralCrossRef Schotsaert M, De Filette M, Fiers W, Saelens X: Universal M2 ectodomain-based influenza A vaccines: preclinical and clinical developments. Expert Rev Vaccines 2009, 8: 499-508. 10.1586/erv.09.6PubMedPubMedCentralCrossRef
20.
go back to reference Jegerlehner A, Schmitz N, Storni T, Bachmann MF: Influenza A vaccine based on the extracellular domain of M2: weak protection mediated via antibody-dependent NK cell activity. J Immunol 2004, 172: 5598-5605.PubMedCrossRef Jegerlehner A, Schmitz N, Storni T, Bachmann MF: Influenza A vaccine based on the extracellular domain of M2: weak protection mediated via antibody-dependent NK cell activity. J Immunol 2004, 172: 5598-5605.PubMedCrossRef
21.
go back to reference Wang R, Song A, Levin J, Dennis D, Zhang NJ, Yoshida H, Koriazova L, Madura L, Shapiro L, Matsumoto A, et al.: Therapeutic potential of a fully human monoclonal antibody against influenza A virus M2 protein. Antiviral Res 2008, 80: 168-177. 10.1016/j.antiviral.2008.06.002PubMedCrossRef Wang R, Song A, Levin J, Dennis D, Zhang NJ, Yoshida H, Koriazova L, Madura L, Shapiro L, Matsumoto A, et al.: Therapeutic potential of a fully human monoclonal antibody against influenza A virus M2 protein. Antiviral Res 2008, 80: 168-177. 10.1016/j.antiviral.2008.06.002PubMedCrossRef
22.
go back to reference Liu W, Zou P, Ding J, Lu Y, Chen YH: Sequence comparison between the extracellular domain of M2 protein human and avian influenza A virus provides new information for bivalent influenza vaccine design. Microbes Infect 2005, 7: 171-177. 10.1016/j.micinf.2004.10.006PubMedCrossRef Liu W, Zou P, Ding J, Lu Y, Chen YH: Sequence comparison between the extracellular domain of M2 protein human and avian influenza A virus provides new information for bivalent influenza vaccine design. Microbes Infect 2005, 7: 171-177. 10.1016/j.micinf.2004.10.006PubMedCrossRef
Metadata
Title
An H5N1 M2e-based multiple antigenic peptide vaccine confers heterosubtypic protection from lethal infection with pandemic 2009 H1N1 virus
Authors
Guangyu Zhao
Shihui Sun
Lanying Du
Wenjun Xiao
Zhitao Ru
Zhihua Kou
Yan Guo
Hong Yu
Shibo Jiang
Yuchun Lone
Bo-Jian Zheng
Yusen Zhou
Publication date
01-12-2010
Publisher
BioMed Central
Published in
Virology Journal / Issue 1/2010
Electronic ISSN: 1743-422X
DOI
https://doi.org/10.1186/1743-422X-7-151

Other articles of this Issue 1/2010

Virology Journal 1/2010 Go to the issue